QuidelOrtho Corp. 10-K Summary: Fiscal Year Ended December 28, 2025
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 28, 2025. QuidelOrtho Corporation is a global provider of diagnostic testing solutions, operating across five reportable segments: North America, EMEA, China, JPAC, and Latin America. The company focuses on four primary business units: Labs, Transfusion Medicine, Point of Care (POC), and Molecular Diagnostics. The reporting period reflects a strategic shift involving the wind-down of the U.S. donor screening portfolio and the discontinuation of the SAVANNA molecular platform development.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Total Revenues | $2,730.2 million | $2,782.9 million | (2)% |
| Net Loss | $(1,131.8) million | $(2,052.0) million | Improvement |
| Adjusted EBITDA (Total) | $1,182.4 million | $1,202.6 million | (2)% |
| Operating Cash Flow | $105.2 million | $83.0 million | 27% |
| Total Debt | $2.65 billion | $2.48 billion | 7% |
| Cash and Equivalents | $169.8 million | $98.3 million | 73% |
| Goodwill Impairment | $700.7 million | $1,822.6 million | N/A |
Note: Gross margin (excluding amortization) was 46.7% for 2025, an improvement from 46.2% in 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 2% year-over-year, driven primarily by a 54% drop in Donor Screening revenue due to the planned U.S. wind-down and a 13% decline in Point of Care revenue due to lower sales of SARS antigen assays. These declines were partially offset by a 6% increase in Labs revenue and a 10% increase in Molecular Diagnostics revenue.
- Significant Non-Cash Charges: The company recorded a $700.7 million non-cash goodwill impairment charge, representing a full impairment of goodwill for the EMEA, China, and Latin America reporting units. This was triggered by a sustained decline in stock price and market capitalization.
- Restructuring and Exit Costs: Restructuring, integration, and other charges totaled $263.6 million, a significant increase from $127.2 million in 2024. This includes $164.1 million related to the SAVANNA Exit and $89.3 million in integration expenses.
- Debt Refinancing: In August 2025, the company entered a new Credit Agreement, refinancing prior debt with $1.15 billion in Term Loan A, $1.45 billion in Term Loan B, and a $700 million Revolving Credit Facility.
Guidance, Outlook, and Risks
Outlook: Management expects demand for respiratory products to continue fluctuating based on seasonal severity and the emergence of new variants. The company anticipates pricing pressures to persist. The wind-down of the U.S. donor screening portfolio is expected to be substantially complete by the first half of 2026, and the SAVANNA Exit is expected to be complete by the first half of 2027.
Strategic Initiatives: The "Optimization Plan" launched in Q2 2025 aims to realign costs with long-term revenue expectations, with cumulative pre-tax charges of approximately $100 million expected through 2027 and net cost savings of $50 million targeted by 2027.
Key Risks:
- Respiratory Product Volatility: Respiratory products accounted for 15% of total revenue in 2025; fluctuations in demand significantly impact operating results.
- Regulatory and Trade: New U.S. tariffs on imports from the U.K., Canada, Mexico, and China are incurring incremental costs. Additionally, the company faces evolving regulatory requirements in the EU (IVDR) and China.
- Collaboration Termination: Discussions to terminate the Joint Business with Grifols resulted in a $65 million charge, with potential for further material adjustments.
- Legal Proceedings: The company is defending against securities class action and derivative lawsuits regarding COVID-19 test sales and SAVANNA assay submissions.
Investor Verification Checklist
- Goodwill Impairment Assumptions: Verify the discounted cash flow and market multiple assumptions used to justify the $700.7 million impairment charge across EMEA, China, and Latin America.
- Respiratory Revenue Trajectory: Monitor the severity of the upcoming flu/RSV season and the specific contribution of non-COVID respiratory products to revenue stability.
- Debt Covenant Compliance: Confirm ongoing compliance with the new Credit Agreement's financial covenants, specifically the maximum Consolidated Leverage Ratio (4.50:1.00 initially) and minimum Interest Coverage Ratio (3.00:1.00).
- Optimization Plan Execution: Track the realization of the projected $50 million in net cost savings against the $100 million in cumulative charges through 2027.
- Grifols Termination Terms: Monitor the final resolution of the Grifols Joint Business termination to ensure the $65 million accrual remains accurate.